USO 24262

A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)(CORT125134-557)

Disease Types: GYN Cancer Research

Eligibility Requirements:

• Histologically confirmed high-grade serous or endometrioid OC/FP/PPC
• Mixed histology of high grade serous and endometrioid are permitted
• Mixed tumors including other histologies are excluded
• Platinum-resistant disease
• Primary plt-refractory disease excluded
• 1-3 prior lines of systemic tx for ovarian cancer
• At least 1 prior line of plt-based therapy required
• Pts with documented BRCA1/2 mutation should have received PARPi
• Hormonal tx are not counted as separate therapies
• Pts may have received prior tx with bevacizumab
• Pts who progressed while receiving weekly paclitaxel or nap-paclitaxel in
PROC setting are excluded
• Concurrent tx with mifepristone or other GR modulators excluded
• Measurable disease by RECIST v1.1

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Williamsburg
• Norfolk (Brock Cancer Center)